Project cooperationUpdated on 19 December 2025
Salivary Liquid Biopsy as a Human-Relevant NAM for Regulatory and Biomedical Research
progect manager at NSight Dynamics s.r.l.
Florence, Italy
About
NSight contributes to consortia addressing HORIZON-HLTH-2026-01-TOOL-03 by providing a human-relevant, non-invasive New Approach Methodology (NAM) based on advanced salivary liquid biopsy.
The NSight technology enables ultra-sensitive detection of molecular biomarkers in saliva, offering a scalable and ethically sustainable alternative or complement to traditional animal-based and invasive testing methods. The approach is particularly suited to regulatory testing, safety assessment and translational biomedical research, in line with the objectives of the topic.
Key contributions include:
-
Human-based NAM: non-invasive salivary liquid biopsy allowing repeated, longitudinal sampling directly in human subjects, increasing biological relevance and reducing reliance on animal models.
-
High-sensitivity molecular endpoints: detection of proteins and other molecular signals with sensitivity several orders of magnitude higher than conventional assays, supporting early and predictive safety and efficacy assessment.
-
Bridging experimental NAMs and regulatory decision-making: saliva-based biomarkers can be used to validate and contextualise data from in vitro, in silico and organ-on-chip models, strengthening translatability to humans.
-
Data integration and standardisation: generation of FAIR, interoperable biomarker datasets suitable for validation, comparison and potential regulatory acceptance.
-
Scalability and ethical sustainability: low-cost, stress-free sampling suitable for large cohorts and repeated measurements, aligned with the 3Rs principles and regulatory expectations for NAM adoption.
Within a consortium, NSight can act as technology provider and WP leader or co-leader for NAM development, biomarker validation and regulatory-relevant endpoint definition. By integrating salivary liquid biopsy into the NAM ecosystem, NSight strengthens the predictive power, human relevance and regulatory impact of next-generation biomedical research methodologies.
Topic
- DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
Type
- Partner seeks Consortium/Coordinator
Organisation
Similar opportunities
Project cooperation
AI-based multimodal monitoring combining wearables, salivary biomarkers and data fusion
- Partner seeks Consortium/Coordinator
- DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
Victoria Barygina
progect manager at NSight Dynamics s.r.l.
Florence, Italy
Project cooperation
Multimodal AI Monitoring for Real-World Implementation of Multisectoral NCD Interventions
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
Victoria Barygina
progect manager at NSight Dynamics s.r.l.
Florence, Italy
Project cooperation
AI-enabled Multimodal Monitoring to Prevent Digital Technology–Related Mental Health Risks in Youth
- Partner seeks Consortium/Coordinator
- DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
Victoria Barygina
progect manager at NSight Dynamics s.r.l.
Florence, Italy